OrthoPediatrics (NASDAQ:KIDS) Receives Buy Rating from Needham & Company LLC

OrthoPediatrics (NASDAQ:KIDS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $37.00 target price on the stock. Needham & Company LLC's price target points to a potential upside of 16.46% from the company's previous close.

A number of other research firms have also commented on KIDS. Truist Financial lowered OrthoPediatrics from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $39.00 to $31.00 in a research note on Thursday, January 25th. JMP Securities reiterated a "market outperform" rating and issued a $50.00 price objective on shares of OrthoPediatrics in a report on Thursday, March 7th.

OrthoPediatrics Stock Performance

Shares of KIDS traded up $1.37 on Wednesday, reaching $31.77. 400,716 shares of the stock traded hands, compared to its average volume of 181,954. The firm has a market cap of $748.15 million, a price-to-earnings ratio of -34.53 and a beta of 1.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.44 and a quick ratio of 2.90. OrthoPediatrics has a 12 month low of $23.10 and a 12 month high of $53.50. The stock's 50-day moving average price is $27.73 and its 200-day moving average price is $28.73.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The business had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. Equities analysts forecast that OrthoPediatrics will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $75,624.19. Following the completion of the transaction, the general counsel now directly owns 52,403 shares in the company, valued at $1,445,798.77. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $75,624.19. Following the completion of the transaction, the general counsel now directly owns 52,403 shares of the company's stock, valued at $1,445,798.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David R. Bailey sold 3,213 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,646.67. Following the transaction, the chief executive officer now directly owns 139,384 shares of the company's stock, valued at $3,845,604.56. The disclosure for this sale can be found here. Insiders sold 17,253 shares of company stock worth $477,375 over the last ninety days. 32.60% of the stock is currently owned by corporate insiders.

Institutional Trading of OrthoPediatrics

Hedge funds have recently made changes to their positions in the business. Point72 Hong Kong Ltd bought a new position in OrthoPediatrics during the 1st quarter worth $26,000. CWM LLC lifted its holdings in OrthoPediatrics by 16,283.3% during the 4th quarter. CWM LLC now owns 983 shares of the company's stock worth $32,000 after buying an additional 977 shares during the period. Almanack Investment Partners LLC. acquired a new position in OrthoPediatrics during the 3rd quarter worth about $34,000. RiverPark Advisors LLC acquired a new position in OrthoPediatrics during the 3rd quarter worth about $35,000. Finally, International Assets Investment Management LLC lifted its stake in shares of OrthoPediatrics by 3,151.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,203 shares of the company's stock valued at $37,000 after purchasing an additional 1,166 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.